<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813434</url>
  </required_header>
  <id_info>
    <org_study_id>PI2013_843_0011</org_study_id>
    <nct_id>NCT02813434</nct_id>
  </id_info>
  <brief_title>Cerebral Amyloid Imaging Using Florbetapir (AV-45) for the Etiological Diagnosis of Poststroke Cognitive Impairment and Dementia</brief_title>
  <acronym>IDEA3</acronym>
  <official_title>Cerebral Amyloid Imaging Using Florbetapir (18F-AV-45) for the Etiological Diagnosis of Poststroke Cognitive Impairment and Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45)
      for the etiological diagnosis of poststroke cognitive impairment and dementia. This study
      stems from two converging objectives: (1) the need to refine characteristics of vascular
      cognitive impairment (VCI) and dementia (VD) in order to propose diagnosis criteria of VCI
      and of mixed dementia and to improve diagnosis criteria of VD and (2) the need to improve the
      etiological diagnosis of poststroke cognitive impairment and dementia. It will take advantage
      from the ongoing GRECOG-VASC study (which determines the cognitive status 6 months poststroke
      in consecutive patients according to a standardized international battery) coordinated by the
      Amiens University Hospital center, the opportunity to perform amyloid imaging in vivo using
      Positron Emission Tomography (PET) and Florbetapir (a production site is located in the city
      of Amiens) and the collaboration between neurology and imaging departments of Amiens
      University hospital.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of positive amyloid retention</measure>
    <time_frame>12 months</time_frame>
    <description>determine the frequency of abnormal amyloid retention using PET with 18F-AV-45 on patients with poststroke cognitive impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final diagnosis</measure>
    <time_frame>12 months</time_frame>
    <description>cognitive impairment or dementia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dementia</condition>
  <condition>Cognition Disorders</condition>
  <arm_group>
    <arm_group_label>Florbetapir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>florbetapir</intervention_name>
    <description>18F-AV-45 or 18F-Florbetapir</description>
    <arm_group_label>Florbetapir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients suffering of parenchymal stroke visualized by imaging (MRI),

          2. patients suffering from cognitive impairment on the 6 months assessment (including
             GRECogVASC patients),

          3. age between 40 and 80 years,

          4. French-speaking,

          5. reliable informant,

          6. agreeing to participate in the study,

          7. affiliation to a social security system,

        Exclusion Criteria:

          1. women of childbearing potential (defined as pre-menopausal, less than 2 years
             postmenopausal, or not surgically sterile), or who are breast-feeding

          2. history of relevant severe drug allergy or hypersensitivity,

          3. patient receiving any investigational medications at least in the 30 last days,

          4. stroke affecting the cerebellum,

          5. mental retardation,

          6. illiteracy,

          7. dementia diagnosed before stroke,

          8. history of schizophrenia or psychiatric illness requiring a stay for &gt; 2 days in a
             psychiatry unit,

          9. persons placed under judicial protection,

         10. comorbidities affecting cognition (respiratory, renal, liver, heart failure),

         11. persistent disturbance of consciousness defined by a score to item 1a of the National
             Institute of Health Stroke Scale (NIHSS) â‰¤ 1,

         12. contraindication to MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier GODEFROY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Godefroy, MD, PhD</last_name>
    <phone>+33 3 22 66 84 47</phone>
    <email>godefroy.olivier@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GODEFROY, MD, PhD</last_name>
      <phone>+33 3 22 66 84 47</phone>
      <email>godefroy.olivier@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebral amyloid imaging</keyword>
  <keyword>Florbetapir</keyword>
  <keyword>18F-AV-45</keyword>
  <keyword>poststroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

